NO982566L - Forbindelser - Google Patents

Forbindelser

Info

Publication number
NO982566L
NO982566L NO982566A NO982566A NO982566L NO 982566 L NO982566 L NO 982566L NO 982566 A NO982566 A NO 982566A NO 982566 A NO982566 A NO 982566A NO 982566 L NO982566 L NO 982566L
Authority
NO
Norway
Prior art keywords
phenyl
optionally substituted
alkyl
fluorine atoms
substituted
Prior art date
Application number
NO982566A
Other languages
English (en)
Other versions
NO982566D0 (no
Inventor
David Cheshire
David Cladingboel
David Hardern
Michael Stocks
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9524920.7A external-priority patent/GB9524920D0/en
Priority claimed from GBGB9609403.2A external-priority patent/GB9609403D0/en
Priority claimed from GBGB9622412.6A external-priority patent/GB9622412D0/en
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Publication of NO982566D0 publication Critical patent/NO982566D0/no
Publication of NO982566L publication Critical patent/NO982566L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Forbindelse av formel (I), hvor X representerer (CH2)nO, (CH2)nS eller C2 alkylen; n representerer l eller 2; Ar1 representerer indanyl, tetrahydronaftyl, naftyl eller fenyl, hvilke sistnevnte to grupper kan være substituert med en eller flere substituenter valgt fra klor, fluor, OR1, O(CH2)mCONR20R21, C(0)R2, C,^ alkyl (eventuelt substituert med ett eller flere fluor- atomer), pyridyl, tiazinyl, fenyl eller C7.9 alkylfenyl hvilke sistnevnte to grupper eventuelt er substituert med en eller flere substituenter valgt fra halogen, nitro, OR3, C,^ alkyl (eventuelt substituert med ett eller flere fluoratomer), C(O)R4, C(0)OR5, C(0)N(R6)R7, CN, CH2OR14, CH2NRI5R16, N(R8)R9, N(RIO)SO2R", N(RI2)C(O)R13, OC(O)R19 og S02NRI7R1S; m representerer et helt tall fra l til 3; R1, R2 og R3 representerer uavhengig H, CMO alkyl (eventuelt substituert med ett eller flere fluor- atomer), C7.9 alkylfenyl eller fenyl, hvilken sistnevnte gruppe eventuelt er substituert med hydroksy; og R4, R5, R6, R7, R8, R9, R10, R», R12, R13, R14, R15, R16, R17, R18, R19, R20 og R21 representerer uavhengig H, C,^ alkyl (eventuelt substituert med ett eller flere fluoratomer) eller fenyl; hvor enhver alkylgruppe kan være avbrutt av ett eller flere oksygenatomer; forutsatt at når X representerer CH2CH2 så kan Ar1 ikke representere fenyl eller fenyl substituert med en eller flere substituenter OR1, hvor R1 representerer C|.IO alkyl;eller et farmasøytisk akseptabelt derivat derav. Disse forbindelsene kan benyttes for behandling av reversibel obstruktiv luftveissykdom eller allergiske tilstander i huden, nesen og øyet.
NO982566A 1995-12-06 1998-06-04 Forbindelser NO982566L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9524920.7A GB9524920D0 (en) 1995-12-06 1995-12-06 Compounds
GBGB9609403.2A GB9609403D0 (en) 1996-05-04 1996-05-04 Compounds
GBGB9622412.6A GB9622412D0 (en) 1996-10-22 1996-10-22 Compounds
PCT/SE1996/001595 WO1997020815A1 (en) 1995-12-06 1996-12-04 Compounds

Publications (2)

Publication Number Publication Date
NO982566D0 NO982566D0 (no) 1998-06-04
NO982566L true NO982566L (no) 1998-07-24

Family

ID=27268017

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982566A NO982566L (no) 1995-12-06 1998-06-04 Forbindelser

Country Status (20)

Country Link
US (1) US5977105A (no)
EP (1) EP0865431A2 (no)
JP (1) JP2000501700A (no)
KR (1) KR19990071968A (no)
CN (1) CN1208403A (no)
AR (1) AR004893A1 (no)
AU (1) AU711772B2 (no)
BR (1) BR9611555A (no)
CZ (1) CZ172498A3 (no)
EE (1) EE9800172A (no)
HU (1) HUP9900143A3 (no)
IL (1) IL124768A0 (no)
IS (1) IS4739A (no)
MX (1) MX9804295A (no)
NO (1) NO982566L (no)
NZ (1) NZ323521A (no)
SA (1) SA97170633A (no)
SK (1) SK73998A3 (no)
TR (1) TR199801000T2 (no)
WO (1) WO1997020815A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2281598A1 (en) * 1997-02-21 1998-08-27 Tetsuya Aono Fused ring compounds, process for producing the same and use thereof
JP2001518115A (ja) 1997-03-25 2001-10-09 アストラゼネカ・アクチエボラーグ 新規なピリジン誘導体およびそれを含有する医薬組成物
EP1019375A1 (en) * 1997-03-25 2000-07-19 Astra Pharmaceuticals Limited Novel pyridine derivatives and pharmaceutical compositions containing them
CN1258296A (zh) * 1997-04-01 2000-06-28 英国阿斯特拉药品有限公司 新的吡啶衍生物及含有它们的药用组合物
SE9803107D0 (sv) * 1998-09-14 1998-09-14 Astra Pharma Prod Novel Compunds
SE9803277D0 (sv) * 1998-09-25 1998-09-25 Astra Pharma Prod Novel compounds
SE9803279D0 (sv) * 1998-09-25 1998-09-25 Astra Pharma Prod Novel compounds
SE9803280D0 (sv) * 1998-09-25 1998-09-25 Astra Pharma Prod Novel compounds
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) * 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
AU2407400A (en) * 1999-01-08 2000-07-24 Vertex Pharmaceuticals Incorporated Process for the formation of intermediates useful for the preparation of pharmaceuticals
SE9901079D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel compounds
CA2314458A1 (en) 1999-08-02 2001-02-02 Kazumi Okuro Process for production of 3-(3-pyridyl)-1-propanol derivatives
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
MX2009004904A (es) * 2006-11-09 2009-05-19 Bausch & Lomb Sintesis de estereoisomeros seleccionados de ciertos alcoholes sustituidos.
CN103450077B (zh) 2007-06-08 2016-07-06 满康德股份有限公司 IRE-1α抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7955287A (en) * 1986-10-14 1988-04-21 G.D. Searle & Co. Pyridine derivatives
AU7975887A (en) * 1986-10-16 1988-04-21 G.D. Searle & Co. Alpha-((phenylmethoxy)methyl)pyridine alkanols
WO1990012006A1 (en) * 1989-04-07 1990-10-18 Pfizer Inc. Substituted 1-[3-(heteroarylmethoxy)phenyl]alkanols and related compounds in the treatment of asthma, arthritis and related diseases

Also Published As

Publication number Publication date
EE9800172A (et) 1998-12-15
HUP9900143A3 (en) 2000-04-28
SK73998A3 (en) 1999-02-11
WO1997020815A1 (en) 1997-06-12
US5977105A (en) 1999-11-02
NO982566D0 (no) 1998-06-04
IL124768A0 (en) 1999-11-30
CN1208403A (zh) 1999-02-17
SA97170633A (ar) 2005-12-03
BR9611555A (pt) 1999-03-02
EP0865431A2 (en) 1998-09-23
HUP9900143A2 (hu) 1999-05-28
TR199801000T2 (xx) 1998-08-21
AU1048097A (en) 1997-06-27
AR004893A1 (es) 1999-03-10
JP2000501700A (ja) 2000-02-15
CZ172498A3 (cs) 1998-12-16
KR19990071968A (ko) 1999-09-27
AU711772B2 (en) 1999-10-21
MX9804295A (es) 1998-09-30
IS4739A (is) 1998-05-12
NZ323521A (en) 1999-10-28

Similar Documents

Publication Publication Date Title
NO982566L (no) Forbindelser
ATE279406T1 (de) Piperidinderivate mit tachykinin-antagonistischer wirkung
DE69423802T2 (de) Indolderivate als 5-HT1-like Agonisten
UA41251C2 (uk) Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
NO159795C (no) Fremgangsmaate for fremstilling av 2-penemforbindelser.
NZ336302A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
ES8203845A1 (es) Procedimiento para preparar derivados de piridoxina
FR2674855B1 (fr) Derives de piperidine, leur preparation et leur application en therapeutique.
DE69202286D1 (de) Verfahren zur Färbung keratinischer Fasern mit Isatin oder Isatinderivaten zusammen mit Aminopyrimidin oder Aminopyridin und Färbemittel.
NZ503822A (en) 2-halo-6-O-substituted erythromycin derivatives, a process for their preparation and pharmaceuticals thereof, useful for treating bacterial infections
NO863457L (no) Fremgangsmaate av ace-inhiberende forbindelser.
DE3869173D1 (de) Amino 5,6,7,8-tetrahydronaphtho(2,3b)furanderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ES2105549T3 (es) Nuevos derivados fenoxi-isobutiricos sustituidos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
DE3861926D1 (de) Polyzyklische aromatische verbindungen, verfahren zu deren herstellung, deren verwendung in menschlicher und tierischer medizin und in der kosmetik.
NO951811L (no) Kinolin- og benzimidazolderivater, deres fremstilling og anvendelse
NO167029C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridinkarboksylsyrederivater
NO952194L (no) Spirofuranonderivater og deres anvendelse ved behandling av neurodegenerative sykdommer
TH34361A (th) สารประกอบ
ATE183750T1 (de) Phosphonyldipeptide zur bekämpfung von kardiovasvakuläre erkrankungen
DE69217148D1 (de) Isoxazole derivate als lichtschutzmittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application